TC Biopharm (Holdings) Plc
TCBPY
$0.335
$0.026.35%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 55.74% | 55.26% | -24.76% | 0.28% | -7.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 108.20% | 108.16% | -71.19% | -86.11% | -- |
| Total Operating Expenses | 18.68% | 18.31% | -43.45% | -14.03% | -4.67% |
| Operating Income | -18.68% | -18.31% | 43.45% | 14.03% | -60.68% |
| Income Before Tax | -12.82% | -12.47% | -404.34% | -246.36% | -148.99% |
| Income Tax Expenses | -15.49% | -15.12% | 64.47% | 71.09% | 58.90% |
| Earnings from Continuing Operations | -12.65% | -12.30% | -301.64% | -446.34% | -262.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.65% | -12.30% | -301.64% | -446.34% | -262.81% |
| EBIT | -18.68% | -18.31% | 43.45% | 14.03% | -60.68% |
| EBITDA | -21.16% | -20.78% | 44.31% | 13.46% | -68.08% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |